ClinicalTrials.gg
RecruitingNCT07847164Updated Sep 29, 2026

Cohort Study on the Prognosis and Influencing Factors in Elderly Patients With Hip Fractures in Multicenter of China

An observational study in Hip Fractures (i.e. Femoral Neck or Intertrochanteric Hip Fractures), sponsored by Beijing Hospital. Recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Beijing Hospital · Observational

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies in Hip Fractures with a site in China — 15 open to participants now, 16 under way, none of them phase 3. Hip Fractures · China.

Planned enrollment
Largest of 17
10,000 · median 600
Started
2024
with 9 others
Observational
17 of 51
4 open now
Primary completion
2027-12
later than 11 of 15 live
Registered
50th of 51
by date

Among the 51 studies in Hip Fractures with a site in China, this one has the largest planned enrollment of the 17 observational ones that give a count, is one of 10 that started in 2024, is one of 17 observational ones, reaches primary completion later than 11 of the 15 other live ones, and was the 50th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

15 of the 51 studies in Hip Fractures with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Hip Fractures with a site in China, or all of them as a file.
02

Study summary

To address the difficulties and problems currently facing large-scale clinical cohort studies in China, and on the basis of the existing project "Construction of Clinical Registration Database and Risk Assessment System for Osteoporosis and Osteoarthritis" under the National Key R\&D Program of the Ministry of Science and Technology, this project aims to target elderly hip fracture-an international public health issue-by collaborating with 38 hospitals across the country to jointly establish the largest specialized cohort for elderly hip fracture in China, thereby providing a data platform and technical support for multicenter clinical cohort studies on elderly hip fracture.

Read the detailed description
  1. Building upon the project of the 14th Five-Year Plan, we aim to further expand the scope by establishing a clinical collaboration system involving multiple tertiary A hospitals across the country. Based on this system, we will define unified inclusion and exclusion criteria for case enrollment and establish the largest national multicenter clinical disease-specific cohort of geriatric hip fractures in China.
  2. We will prospectively collect baseline information, social data, pre-existing comorbidities and other unrelated medical history, genetic-related information, physical examination findings, laboratory and biochemical data, imaging examinations, and other relevant data from elderly patients (aged 60 years and above) with hip fractures.
  3. We will collect information on diagnosis and treatment during the patient care episode (including surgery, non-surgical management, anti-osteoporosis therapy, etc.) to build a clinical diagnosis and treatment information database.
  4. After the completion of the treatment course, we will conduct a 1- to 2-year follow-up, focusing on survival status, re-fractures, medical comorbidities, surgery-related complications, and post-discharge home care arrangements. This will enable the development of a standardized follow-up system for prognostic research on geriatric hip fractures.
03

Conditions studied

  • Hip Fractures (i.e. Femoral Neck or Intertrochanteric Hip Fractures)

Browse trials for

Keywords

  • Hip fractures (i.e. femoral neck or intertrochanteric hip fractures)
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Hip fracture inpatients at grade-A tertiary hospitals across China

Eligibility criteria

Inclusion Criteria:1: The subjects are of Chinese nationality.

2: The subject is 60 years of age or older (including the boundary value)

3:The subject has been diagnosed with hip fracture by imaging, including femoral neck fracture, intertrochanteric fracture of femur, and subtrochanteric fracture of femur

4: Patients who were hospitalized for hip fracture treatment (surgical or conservative) after September 1, 2022

5: The subject can fully understand and sign the form.

-

Exclusion Criteria:1: Pathological fractures caused by primary or tumors of bone or bone developmental disorders

2: Patients with peri-implant fractures or polytrauma (multiple injuries resulting from a single traumatic event in which two or more anatomical sites in the body are severely injured, with one of them being severely injured even in the absence of the traumatic event also posing a life-threatening risk)

3: Subjects who, in the opinion of the investigator, are not eligible for enrollment in the study.

-

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • A cohort of elderly patients with hip fracture

    A cohort of elderly patients with hip fracture

06

What researchers measure

Primary outcomes

  1. death

    Post-hip fracture mortality (yes/no)

    Time frame: Six months, one year, and two years after hip fracture

Secondary outcomes

  1. Clavien-Dindo classification of complications

    Clavien-Dindo classification of complications

    Time frame: Six months, one year, and two years after hip fracture

  2. Conservative treatment status for patients managed non-surgically

    Conservative treatment status for patients managed non-surgically

    Time frame: Six months, one year, and two years after hip fracture

  3. Imaging data

    Imaging data

    Time frame: one day,Six months, one year, and two years after hip fracture

  4. Other new adverse events

    Other new adverse events

    Time frame: Six months, one year, and two years after hip fracture

  5. Place of residence at follow-up.

    Place of residence at follow-up.

    Time frame: Six months, one year, and two years after hip fracture

  6. Post-hospital care

    Post-hospital care

    Time frame: Six months, one year, and two years after hip fracture

  7. Anti-osteoporosis treatment status

    Anti-osteoporosis treatment status

    Time frame: Six months, one year, and two years after hip fracture

  8. EQ-5D Quality of Life score

    EQ-5D Quality of Life score

    Time frame: Six months, one year, and two years after hip fracture

  9. Time to discontinuation of strict bed rest

    Time to discontinuation of strict bed rest

    Time frame: Six months, one year, and two years after hip fracture

  10. Refracture event

    Refracture event

    Time frame: Six months, one year, and two years after hip fracture

  11. FAC Functional Walking Scale

    FAC Functional Walking Scale

    Time frame: Six months, one year, and two years after hip fracture

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) from this nationwide multicenter prospective cohort of elderly patients with hip fracture will be shared. The shared dataset includes: (1) demographic and baseline characteristics (age, sex, comorbidities, frailty and functional status); (2) injury and treatment details (fracture type, surgical procedure, anesthesia method, timing of surgery); (3) perioperative management data (blood transfusion, rehabilitation); and (4) outcome data at each follow-up time point (mortality, complications, reoperation, functional scores such as FAC or EQ-5D, and quality of life). All direct identifiers (name, ID number, phone, address, hospital record number) will be removed before sharing. Data from individual centers will be pooled after harmonization across sites.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: The study protocol and statistical analysis plan are available immediately upon study registration. De-identified IPD and the analytic code will be available within 1 year after publication of the primary outcome results in a peer-reviewed journal, and will remain available for at least 5 years after the final study report is submitted.

Access criteria: Access will be open to researchers from academic institutions, hospitals, or public health organizations worldwide with a methodologically sound research proposal consistent with the original informed consent. To request access, researchers should submit a proposal (including research question, analysis plan, and publication plan) to the corresponding author / coordinating center by email. Proposals will be reviewed by the study steering committee within 30 days. Approved researchers will be required to sign a data use agreement stipulating that data will be used only for the approved purpose, will not be redistributed, and that results will be shared with the study group before publication. De-identified data will be transferred through a secure file-sharing platform.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.

Of 107 non-industry observational studies under Hip Fractures, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 65. This study's planned 36 months is above that.

Counting every sponsor, half of 124 studies reached it within 28 months; a quarter within 12 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 29, 2026
StartActual
Dec 1, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847164
Lead sponsor
Beijing Hospital
Responsible party
wenliangyuan (Chief Expert, Department of Orthopaedics, Beijing Hospital, Beijing Hospital) — Principal investigator
First posted
Sep 29, 2026
Start date
Dec 1, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

zhaoshuo he, doctoral degree
Contact
1747493731@qq.com
+86 +17852326007 ext. 8610-8513-6171
ze zhang, doctoral degree
Contact
1911210691@pku.edu.cn
+86 +18810599419
liangyuan wen, doctoral degree
study chair · Beijing Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion